Skip to main content

Breast Cancer Research and Treatment

Ausgabe 1/2013

Inhalt (21 Artikel)

Review

Trastuzumab-related cardiac events in the treatment of early breast cancer

Georgeta Fried, Tslil Regev, Mor Moskovitz

Open Access Preclinical study

Reduction of tumor angiogenesis induced by desmopressin in a breast cancer model

Giselle V. Ripoll, Juan Garona, Marina Pifano, Hernan G. Farina, Daniel E. Gomez, Daniel F. Alonso

Preclinical study

MicroRNA signatures in hereditary breast cancer

Rosa Murria Estal, Sarai Palanca Suela, Inmaculada de Juan Jiménez, Cecilia Egoavil Rojas, Zaida García-Casado, María José Juan Fita, Ana Beatriz Sánchez Heras, Ángel Segura Huerta, Isabel Chirivella González, Dolors Sánchez-Izquierdo, Marta Llop García, Eva Barragán González, Pascual Bolufer Gilabert

Open Access Preclinical study

Reevaluation of the proposed autocrine proliferative function of prolactin in breast cancer

Louise Maymann Nitze, Elisabeth Douglas Galsgaard, Nanni Din, Vibe Luja Lund, Birgitte Bruun Rasmussen, Martin Werner Berchtold, Leif Christensen, Svetlana Panina

Preclinical Study

Peripheral blood mononuclear cells of patients with breast cancer can be reprogrammed to enhance anti-HER-2/neu reactivity and overcome myeloid-derived suppressor cells

Kyle K. Payne, Christine K. Zoon, Wen Wan, Khin Marlar, Rebecca C. Keim, Mehrab Nasiri Kenari, A. Latif Kazim, Harry D. Bear, Masoud H. Manjili

Clinical Trial

Impact of body mass index and weight fluctuation on lymphedema risk in patients treated for breast cancer

Lauren S. Jammallo, Cynthia L. Miller, Marybeth Singer, Nora K. Horick, Melissa N. Skolny, Michelle C. Specht, Jean O’Toole, Alphonse G. Taghian

Open Access Clinical Trial

Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil–epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy

S. Ohno, L. W. C. Chow, N. Sato, N. Masuda, H. Sasano, F. Takahashi, H. Bando, H. Iwata, T. Morimoto, S. Kamigaki, T. Nakayama, S. Nakamura, K. Kuroi, K. Aogi, M. Kashiwaba, H. Yamashita, K. Hisamatsu, Y. Ito, Y. Yamamoto, T. Ueno, E. Fakhrejahani, N. Yoshida, M. Toi

Clinical Trial

Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patients

Anja Welt, Mitra Tewes, Bahriye Aktas, Oliver Hoffmann, Marcel Wiesweg, Saskia Ting, Henning Reis, Karl Worm, Heike Richly, Jörg Hense, Michael R. Palmer, Benjamin H. Lee, Johanna Wendling, Josef Kossow, Max E. Scheulen, Cathrin Lehnerdt, Marzena Kohl, Cordula Derks, Silke Skottky, Ulrike Haus, Kurt W. Schmid, Rainer Kimmig, Martin Schuler, Stefan Kasper

Open Access Clinical trial

Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)

David Miles, José Baselga, Dino Amadori, Patrapim Sunpaweravong, Vladimir Semiglazov, Adam Knott, Emma Clark, Graham Ross, Sandra M. Swain

Clinical trial

Preference weights for chemotherapy side effects from the perspective of women with breast cancer

I. Kuchuk, N. Bouganim, K. Beusterien, J. Grinspan, L. Vandermeer, S. Gertler, S. F. Dent, X. Song, R. Segal, S. Mazzarello, F. Crawley, G. Dranitsaris, M. Clemons

Clinical trial

Risk of docetaxel-induced peripheral neuropathy among 1,725 Danish patients with early stage breast cancer

L. Eckhoff, A. S. Knoop, M.-B. Jensen, B. Ejlertsen, M. Ewertz

Clinical trial

Favorable modulation of benign breast tissue and serum risk biomarkers is associated with >10 % weight loss in postmenopausal women

Carol J. Fabian, Bruce F. Kimler, Joseph E. Donnelly, Debra K. Sullivan, Jennifer R. Klemp, Brian K. Petroff, Teresa A. Phillips, Trina Metheny, Sonya Aversman, Hung-wen Yeh, Carola M. Zalles, Gordon B. Mills, Stephen D. Hursting

Epidemiology

Do alternative methods of measuring tumor size, including consideration of multicentric/multifocal disease, enhance prognostic information beyond TNM staging in women with early stage breast cancer: an analysis of the NCIC CTG MA.5 and MA.12 clinical trials

J. F. Hilton, N. Bouganim, B. Dong, J. W. Chapman, A. Arnaout, F. O’Malley, K. A. Gelmon, R. Yerushalmi, M. N. Levine, V. H. C. Bramwell, T. J. Whelan, K. I. Pritchard, L. E. Shepherd, M. Clemons

Epidemiology

Long-term surveillance mammography and mortality in older women with a history of early stage invasive breast cancer

Diana S. M. Buist, Jaclyn L. F. Bosco, Rebecca A. Silliman, Heather Taffet Gold, Terry Field, Marianne Ulcickas Yood, Virginia P. Quinn, Marianne Prout, Timothy L. Lash

Epidemiology

Reproductive factors and risk of premenopausal breast cancer by age at diagnosis: Are there differences before and after age 40?

Erica T. Warner, Graham A. Colditz, Julie R. Palmer, Ann H. Partridge, Bernard A. Rosner, Rulla M. Tamimi

Epidemiology

The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation

Adriana Valentini, Jan Lubinski, Tomasz Byrski, Parviz Ghadirian, Pal Moller, Henry T. Lynch, Peter Ainsworth, Susan L. Neuhausen, Jeffrey Weitzel, Christian F. Singer, Olufunmilayo I. Olopade, Howard Saal, Dominique Stoppa Lyonnet, William D. Foulkes, Charmaine Kim-Sing, Siranoush Manoukian, Dana Zakalik, Susan Armel, Leigha Senter, Charis Eng, Eva Grunfeld, Anna M. Chiarelli, Aletta Poll, Ping Sun, Steven A. Narod

Open Access Epidemiology

Validation of Rosner–Colditz breast cancer incidence model using an independent data set, the California Teachers Study

B. A. Rosner, G. A. Colditz, S. E. Hankinson, J. Sullivan-Halley, J. V. Lacey Jr., L. Bernstein

Open Access Brief Report

Prospective clinical experience with research biopsies in breast cancer patients

Ines Vaz-Luis, Catherine A. Zeghibe, Elizabeth S. Frank, Jessica Sohl, Kimberly E. Washington, Stuart G. Silverman, Joseph M. Fonte, Erica L. Mayer, Beth A. Overmoyer, Andrea L. Richardson, Ian E. Krop, Eric P. Winer, Nancy U. Lin

Brief Report

Distinct nuclear receptor expression in stroma adjacent to breast tumors

Kevin C. Knower, Ashwini L. Chand, Natalie Eriksson, Kiyoshi Takagi, Yasuhiro Miki, Hironobu Sasano, Jane E. Visvader, Geoffrey J. Lindeman, John W. Funder, Peter J. Fuller, Evan R. Simpson, Wayne D. Tilley, Peter J. Leedman, J. Dinny Graham, George E. O. Muscat, Christine L. Clarke, Colin D. Clyne

Erratum

Erratum to: CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy

Wendy A. Teft, Inna Y. Gong, Brian Dingle, Kylea Potvin, Jawaid Younus, Theodore A. Vandenberg, Muriel Brackstone, Francisco E. Perera, Yun-Hee Choi, Guangyong Zou, Robin M. Legan, Rommel G. Tirona, Richard B. Kim

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.